Gilead Sciences Newswire

Comprehensive Real-Time News Feed for Gilead Sciences.

Results 1 - 20 of 866 in Gilead Sciences

  1. Gilead Earnings Preview: Non-Sovaldi Sales Bogey Of $2.94B May Be UnrealisticRead the original story w/Photo

    20 min ago | Seeking Alpha

    Gilead Sciences, Inc. reports Q2 earnings tomorrow. Gilead is a biopharmaceutical company that develops and markets medicines for unmet needs.

    Comment?

  2. Doctors' Dilemma: Who Gets Costly Cure for Deadly VirusRead the original story

    8 hrs ago | Bloomberg

    ... were refusing to pay for the $84,000 drug. So far only about 50 of the patients have received the medicine, Gilead Sciences Inc.'s Sovaldi . Not since AIDS drug cocktails were introduced almost two decades ago has a medical breakthrough set up such ...

    Comment?

  3. Netflix falls on lower quarterly forecastRead the original story

    14 hrs ago | SFGate

    ... in Mexico and acquire rights to expand into Germany, France and four other European countries this fall. Gilead Sciences reports second-quarter earnings Wednesday, and analysts predict the Foster City drugmaker will post net income of $2.73 billion, ...

    Comment?

  4. Alexion, 3 Other Top Biotechs Reporting Earn...Read the original story

    Yesterday | Investor's Business Daily

    The four highest-rated of the market's seven big-cap biotechs are set to report second-quarter earnings this week, each with its own unique storyline.

    Comment?

  5. Alexion, 3 Other Top Biotechs Reporting EarningsRead the original story

    16 hrs ago | Investor's Business Daily

    The four highest-rated of the market's seven big-cap biotechs are set to report second-quarter earnings this week, each with its own unique storyline.

    Comment?

  6. 3 Things You Need to Watch on Gilead Sciences Inc. Earnings CallRead the original story

    18 hrs ago | The Motley Fool

    Here are three things investors should pay attention to during the conference call.

    Comment?

  7. HIV pills show more promise to prevent infectionRead the original story

    Yesterday | R & D

    ... treating HIV. It's a combination of two drugs, tenofovir and emtricitabine, or FTC, made by California-based Gilead Sciences Inc. Its wholesale price is $800 a month in the U.S. but generic versions are available in other countries and they cost as ...

    Comment?

  8. Taking HIV medicine to prevent infection shows more promise; even less than daily use helpsRead the original story

    Yesterday | Western Star

    ... treating HIV. It's a combination of two drugs, tenofovir and emtricitabine, or FTC, made by California-based Gilead Sciences Inc. Its wholesale price is $800 a month in the U.S. but generic versions are available in other countries and they cost as ...

    Comment?

  9. Hep C drugs could add $300 to premiumsRead the original story w/Photo

    Monday | SFGate

    Gilead Sciences' new hepatitis C drug receives as much praise for its healing powers as it receives criticism of its price, $84,000 for 12 weeks.

    Comment?

  10. Costly hepatitis C drugs could add $300 to every American's yearly premium, CVS saysRead the original story w/Photo

    Monday | Seattle Post-Intelligencer

    Gilead Sciences' new hepatitis C drug receives as much praise for its healing powers as it receives criticism of its price, $84,000 for 12 weeks.

    Comment?

  11. How Will Gilead Sciences Stock Be Affected by Solvadi Hepatitis C Finding?Read the original story w/Photo

    Monday | TheStreet.com

    ... of stocks that can potentially TRIPLE in the next 12 months. Learn more. TheStreet Ratings team rates GILEAD SCIENCES INC as a Buy with a ratings score of A. TheStreet Ratings Team has this to say about their recommendation: "We rate GILEAD SCIENCES ...

    Comment?

  12. Biotechs Have Their 'Irrational Exuberance' Moment: Time To Buy More?Read the original story w/Photo

    Monday | Seeking Alpha

    ... last week, large ones also got slammed. Biogen Idec (NASDAQ: BIIB ) fell more than 7% after that statement. Gilead Sciences (NASDAQ: GILD ) fell 5% peak-to-trough. Small ones got dumped big-time. Is it but a passing storm, though? Fed Chairman Alan ...

    Comment?

  13. Gilead Sciences Under Investigation for Over-Charging for Hepatitis C PillRead the original story w/Photo

    Monday | OpEdNews

    Gilead Sciences of San Francisco is under investigation by the U.S. Senate Finance Committee for charging $84,000 for a 12 week course of a new drug to treat hepatitis C. Gilead sells the exact same course for $900 in poor countries like Egypt and India. 1 comment

  14. How Will Gilead Sciences (GILD) Stock Be Affected By Solvadi Hepatitis C Finding?Read the original story w/Photo

    Monday | TheStreet.com

    ... of stocks that can potentially TRIPLE in the next 12 months. Learn more. TheStreet Ratings team rates GILEAD SCIENCES INC as a Buy with a ratings score of A. TheStreet Ratings Team has this to say about their recommendation: "We rate GILEAD SCIENCES ...

    Comment?

  15. Morning 10: NY locavore push | Wealthy staying put | Dodd-Frank targetedRead the original story

    Monday | New York Business.com

    ... office concluded. [ The New York Times ] Merck & Co. is among the companies charging that California-based Gilead Sciences Inc. infringed on their copyright with the launch of its hepatitis C drug, Sovaldi. Hepatitis C drug sales are expected to ...

    Comment?

  16. Biotech Enters Reporting Season With Large Caps Central To Sector PerformanceRead the original story

    Friday Jul 18 | Benzinga

    ... Sclerosis drug Copaxone as well as the pending launch of its Hemophilia A drug Eloctate. Another large cap, Gilead Sciences, Inc. (NASDAQ: GILD ) is reporting July 23, Mehrotra said the most important headline number will be revenue for the ...

    Comment?

  17. Gilead: 50% Upside From HereRead the original story w/Photo

    Friday Jul 18 | Seeking Alpha

    Gilead Sciences has appreciated more than 20% over the past three months easily besting the performance of the S&P 500.

    Comment?

  18. Stocks Up In Late Trade; AerCap Nears ResistanceRead the original story

    Friday Jul 18 | Investor's Business Daily

    Stocks continued to add to broad gains in late trading Friday and were on pace to end modestly higher on the week.

    Comment?

  19. NASH a Big Opportunity For Gilead Sciences, Inc.Read the original story w/Photo

    Friday Jul 18 | Insider Monkey

    After being a dominant player in the hepatitis C market with its drug Sovaldi, Gilead Sciences, Inc. is now eyeing to monetize from the next global epidemic, NASH, or nonalcoholic steatohepatitis.

    Comment?

  20. Analyst Upgrades: Microsoft Corporation, Gilead Sciences, Inc., and Amgen, Inc.Read the original story

    Friday Jul 18 | SchaeffersResearch.com

    ... upside of nearly 66% to yesterday's close at $85.07. Most analysts have slightly tamer expectations for Gilead Sciences, Inc., as the average 12-month price target weighs in at $101.57. The stock is up 13.3% in 2014, and is currently testing support ...

    Comment?